Quelling the Vicious Vortex: Targeting Neutrophil Serine Proteases in Non-Cystic Fibrosis Bronchiectasis
Program Information

Hybrid Industry Early Morning Symposium at the ERS International Congress 2023

07:15 – 08:15 CEST
Breakfast will be served

Allianz MiCo

Coral 2, Hall 4
Milano Convention Centre
V.le Egnardo
20149 Milano, Italy

Also Available to Virtual Attendees via Online Simulcast

Doreen J. Addrizzo-Harris, MD, FCCP

Doreen J. Addrizzo-Harris, MD, FCCP
Professor, Medicine
Associate Director, Clinical and Academic Affairs
Co-Director, NYU Bronchiectasis/NTM Clinical and Translational Program
NYU Grossman School of Medicine
New York, United States
Stefano Aliberti, MD

Stefano Aliberti, MD
Professor, Respiratory Diseases
Humanitas University
Chief, Respiratory Unit
IRCCS Humanitas Research Hospital
Milan, Italy
Pieter C. Goeminne, MD, PhD

Pieter C. Goeminne, MD, PhD
Staff Member, Department of Respiratory Disease
VITAZ Hospital
Saint-Nicholas, Belgium

In this symposium, experts and an experienced patient share clinical pearls for the timely diagnosis and management of non-cystic fibrosis bronchiectasis (NCFBE). Do not miss this opportunity to learn more about emerging NCFBE treatment options aimed at targeting the vicious vortex of neutrophil-mediated inflammation and lung damage.

5 minutes

Doreen J. Addrizzo-Harris, MD, FCCP
10 minutes

Doreen J. Addrizzo-Harris, MD, FCCP and Panel including Experienced Patient
15 minutes

Pieter C. Goeminne, MD, PhD and Panel including Experienced Patient
20 minutes

Stefano Aliberti, MD and Panel including Experienced Patient
10 minutes

All Faculty

Respiratory clinicians managing patients with non-cystic fibrosis bronchiectasis (NCFBE).

Upon completion of this activity, participants should be better able to:

  • Identify the burden of non-cystic fibrosis bronchiectasis (NCFBE) and its exacerbations on patient QoL
  • Utilize clinical practice guidelines to facilitate early NCFBE recognition and diagnosis
  • Assess the potential impact of targeting neutrophil serine protease (NSP) activation on the treatment of NCFBE

This educational activity was independently developed by RMEI Medical Education, LLC. All faculty and planner relevant financial relationships were identified and mitigated and RMEI Medical Education, LLC has reviewed the content and determined it to be fair, balanced, and without commercial bias.

Supported by an educational grant from Insmed.

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.

There is no fee for this educational activity.

Facebook  Twitter  LinkedIn

Additional educational activities offered by RMEI Medical Education, LLC can be found
at www.RMEI.com or by calling toll-free (866) 770-RMEI.